drugset
drugset / Trial / NCT05345912

Pharmacokinetics and Safety of 'CG-745 IV' and 'CG-750' in Healthy Male Adults

NCT05345912 ↗

Phase 1 Completed 24 enrolled CrystalGenomics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A randomized, placebo-controlled, dose-escalation, crossover study.

Timeline

Start
2019-12-16
Primary completion
2020-09-18
Completion
2021-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject CG-750 Unknown 125 mg Oral
Subject CG-750 Unknown 375 mg Oral
Subject CG-750 Unknown 750 mg Oral
Subject CG200745 Small molecule 125 mg Intravenous
Subject CG200745 Small molecule 250 mg Intravenous

Indications

No indication recorded.